Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pediatric Endocrinology

Treatment and Management of Low Blood Sugar

At a Glance

Some children with HNF1A-related hyperinsulinism are unusually sensitive to diazoxide, so treatment may require cautious dosing and close monitoring. Emergency glucagon, regular feeding, and a written low-blood-sugar plan help keep children safe.

Managing HNF1A-related hyperinsulinism involves two main goals: keeping blood sugar in a safe range to protect the brain and transitioning from emergency hospital care to a sustainable routine at home. Because this condition is caused by a specific genetic change, your child’s response to medication may be different—and often much more sensitive—than other children with low blood sugar [1][2].

Immediate Care: Stabilizing Blood Sugar

When a baby experiences a severe drop in blood sugar, the immediate priority is to raise it quickly and safely. In a hospital setting, this usually involves two main tools:

  • Intravenous (IV) Dextrose: A concentrated sugar solution delivered directly into the bloodstream to provide an immediate source of energy [3].
  • Glucagon: This is a hormone that tells the liver to release its stored sugar into the blood [4]. It can be given as a quick injection or as a continuous infusion in the hospital to help stabilize levels and reduce the amount of IV sugar needed [5].

Home Emergency Plan for Hypoglycemia
Your endocrinologist will provide an individualized, written emergency plan for lows. Do not delay emergency treatment while trying to obtain a confirmatory reading if your child is symptomatic.

  • If conscious and safely able to swallow: Give a fast-acting carbohydrate (e.g., glucose gel, juice) and recheck in 15 minutes.
  • If unconscious, seizing, or unable to swallow: Do NOT give anything by mouth. Use your prescribed rescue glucagon injection and call emergency services immediately.

Diazoxide: The Primary Medication

Diazoxide is the standard first-line medication for persistent hyperinsulinism [2]. It works by opening “channels” in the pancreatic cells to stop them from releasing too much insulin [6].

A Note on Sensitivity: A hallmark of some reported HNF1A-related cases is an unusual sensitivity to diazoxide [1]. While a standard starting dose for many infants with hyperinsulinism is 5 mg/kg/day, this can cause dangerously high blood sugar (hyperglycemia) in some children with an HNF1A variant [1][2]. To avoid this, specialists in some case reports used a much lower starting dose—such as 0.7 to 2 mg/kg/day—with very slow increases over time [1]. This is an example, not a universal prescription; never start, increase, decrease, or stop diazoxide except under your treating team’s direction. Your care team will monitor your child closely to find the smallest dose that keeps their sugar levels stable.

Monitoring for Side Effects

While diazoxide is effective, it requires careful monitoring because it can affect other systems in the body. Serious side effects include:

  • Fluid Retention: The body may hold onto too much water and salt, which can lead to swelling (edema) or put stress on the heart [7]. To manage this, doctors may prescribe a thiazide diuretic (a “water pill”) alongside diazoxide [8][9]. Do not restrict an infant’s fluids on your own, as this can be hazardous.
  • Pulmonary Hypertension: This is a rare but serious condition where the blood pressure in the lungs becomes too high [8]. Doctors typically use an echocardiogram (an ultrasound of the heart) to check for this according to locally recommended baseline and follow-up schedules [10].
  • Blood Count Changes: Diazoxide can sometimes lower the number of infection-fighting white blood cells (neutropenia) or blood-clotting cells (thrombocytopenia) [9][11].
  • Hyperuricemia: This is an increase in uric acid in the blood, which can affect the kidneys [9].

Urgent Warning Signs: Seek emergency help if you observe breathing difficulty, a blue or gray color, marked swelling, rapid weight gain, poor feeding, or unusual sleepiness. Your medical team will perform regular blood tests and physical exams to catch these issues early.

Daily Life and Monitoring at Home

Beyond medication, your child’s daily routine will center on consistent energy delivery and blood sugar tracking.

  • Frequent Feedings: Providing regular meals—sometimes enriched with extra calories or complex carbohydrates like glucose polymers—helps maintain a steady supply of sugar [4][12]. Your care team may prescribe continuous feeds or tube-feeding support if needed.
  • Continuous Glucose Monitors (CGM): These wearable sensors provide real-time updates on your child’s sugar trends [13]. While very helpful for seeing “where the sugar is going,” they are less accurate when blood sugar is low [14]. A home glucose meter (finger-stick) remains a confirmatory tool, but act immediately on symptoms of a severe low without delaying for a finger-stick [15][16].

By combining a cautious approach to medication with consistent daily monitoring, you and your medical team can create a safe environment for your child to grow and thrive.

Common questions in this guide

How is severe low blood sugar treated in a child with HNF1A-related hyperinsulinism?
Severe hypoglycemia is usually stabilized in the hospital with intravenous dextrose, which supplies sugar directly to the bloodstream, and sometimes glucagon, which prompts the liver to release stored sugar. For ongoing hyperinsulinism, diazoxide is commonly used under close specialist supervision.
What should I do if my child is having a dangerous low blood sugar episode?
If your child is awake and can safely swallow, give the fast-acting carbohydrate in the child's emergency plan and recheck the blood sugar in 15 minutes. If your child is unconscious, having a seizure, or cannot swallow, give nothing by mouth; use the prescribed rescue glucagon and call emergency services immediately.
Why might my child need a very low dose of diazoxide?
Some children with an HNF1A genetic change respond very strongly to diazoxide, so a usual dose can cause dangerously high blood sugar. The endocrinology team may therefore start with a much lower dose and increase it slowly; caregivers should never change the dose without medical direction.
Which diazoxide side effects require urgent medical attention?
Seek urgent medical help for breathing difficulty, blue or gray skin color, marked swelling, rapid weight gain, poor feeding, or unusual sleepiness. These signs can indicate serious problems such as fluid buildup or high blood pressure in the lungs while taking diazoxide.
How can we help keep our child's blood sugar stable at home?
Regular feedings, sometimes with extra calories, complex carbohydrates, continuous feeds, or tube feeding, can help keep blood sugar steady. A continuous glucose monitor shows trends, but a finger-stick meter may be needed to confirm a low reading because these monitors can be less accurate when blood sugar is low.
What monitoring does my child need while taking diazoxide?
The medical team may use echocardiograms to check the heart and lungs, blood counts, other blood tests, physical examinations, and locally recommended follow-up visits. The exact schedule depends on your child's situation and should be provided by the treating team.

Get notified when new evidence is published on Hyperinsulinism due to HNF1A deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    Case report: A novel HNF1A variant linked to gestational diabetes, congenital hyperinsulinism, and diazoxide hypersensitivity.

    Chandran S, Verma D, Rajadurai VS, Yap F

    Frontiers in endocrinology 2024; (15()):1471596 doi:10.3389/fendo.2024.1471596.

    PMID: 39421536
  2. 2

    From standard to individualized diazoxide therapy in congenital hyperinsulinism: a narrative review.

    Wong T, Chan D, Chua C, et al.

    Frontiers in pharmacology 2026; (17()):1781424 doi:10.3389/fphar.2026.1781424.

    PMID: 41982675
  3. 3

    Congenital Hyperinsulinism - Notes for the General Pediatrician.

    Estebanez MS, Worth C, Banerjee I

    Indian pediatrics 2024; (61(6)):578-584.

    PMID: 38584412
  4. 4

    Congenital Hyperinsulinism.

    Sims K

    NeoReviews 2021; (22(4)):e230-e240 doi:10.1542/neo.22-4-e230.

    PMID: 33795398
  5. 5

    The Effect of Continuous Intravenous Glucagon on Glucose Requirements in Infants with Congenital Hyperinsulinism.

    Hawkes CP, Lado JJ, Givler S, De Leon DD

    JIMD reports 2019; (45()):45-50 doi:10.1007/8904_2018_140.

    PMID: 30311139
  6. 6

    A Novel HNF4A Mutation Causing Three Phenotypic Forms of Glucose Dysregulation in a Family.

    Chandran S, Rajadurai VS, Hoi WH, et al.

    Frontiers in pediatrics 2020; (8()):320 doi:10.3389/fped.2020.00320.

    PMID: 32670997
  7. 7

    Safety and effectiveness, including intelligence prognosis, of diazoxide in pediatric patients with hyperinsulinemic hypoglycemia: special survey in Japan (long-term, all-case survey).

    Fukutomi M, Shimodera M, Maeda Y, et al.

    Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology 2018; (27(3)):131-143 doi:10.1297/cpe.27.131.

    PMID: 30083030
  8. 8

    Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom.

    Chen SC, Dastamani A, Pintus D, et al.

    Clinical endocrinology 2019; (91(6)):770-775 doi:10.1111/cen.14096.

    PMID: 31520536
  9. 9

    Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.

    Herrera A, Vajravelu ME, Givler S, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(12)):4365-4372 doi:10.1210/jc.2018-01613.

    PMID: 30247666
  10. 10

    Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.

    Brar PC, Heksch R, Cossen K, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(12)) doi:10.1210/clinem/dgaa543.

    PMID: 32810255
  11. 11

    Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis.

    Chen X, Feng L, Yao H, et al.

    PloS one 2021; (16(2)):e0246463 doi:10.1371/journal.pone.0246463.

    PMID: 33571197
  12. 12

    Feeding practices and nutritional management of infants with transient and congenital hyperinsulinism: A tertiary single-center retrospective study.

    Cheng L, O'Connor G, Harris E, et al.

    Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2026; (41(5)):1466-1475 doi:10.1002/ncp.70146.

    PMID: 42370820
  13. 13

    Families' Experiences of Continuous Glucose Monitoring in the Management of Congenital Hyperinsulinism: A Thematic Analysis.

    Auckburally SH, Worth C, Salomon-Estebanez M, et al.

    Frontiers in endocrinology 2022; (13()):894559 doi:10.3389/fendo.2022.894559.

    PMID: 35928891
  14. 14

    First Accuracy and User-Experience Evaluation of New Continuous Glucose Monitoring System for Hypoglycemia Due to Hyperinsulinism.

    Worth C, Worthington S, Auckburally S, et al.

    Journal of diabetes science and technology 2025; (19(5)):1280-1285 doi:10.1177/19322968241245923.

    PMID: 38616550
  15. 15

    The hypoglycaemia error grid: A UK-wide consensus on CGM accuracy assessment in hyperinsulinism.

    Worth C, Dunne MJ, Salomon-Estebanez M, et al.

    Frontiers in endocrinology 2022; (13()):1016072 doi:10.3389/fendo.2022.1016072.

    PMID: 36407313
  16. 16

    Inpatient continuous glucose monitoring halves the risk of hypoglycemia in patients with hyperinsulinism.

    Chandra C, De Silva S, Worthington S, et al.

    Frontiers in endocrinology 2026; (17()):1943475 doi:10.3389/fendo.2026.1943475.

    PMID: 42959150

This page is for informational purposes only and does not constitute medical advice. Your child's endocrinology team should direct diazoxide dosing, emergency treatment, and monitoring.